Home>Topics>Stocks>Neurocrine Biosciences

Neurocrine Biosciences NBIX

  1. All
  2. Commentary
  3. Headlines
    1. 2 Biotechs Race To Treat Movement Disorders

      Headlines

      Fri, 27 Jun 2014

      safety and tolerability of a 60-year old drug. That drug is tetrabenazine, and the two companies are Neurocrine Biosciences ( NBIX ) and Auspex Pharmaceuticals ( ASPX ). Below we provide a brief background on tetrabenazine, take a detailed

    2. Neurocrine In "Hurry Up And Wait" Mode

      Headlines

      Wed, 11 Jun 2014

      used in reference to war, but it can also apply to biotech investing, to a limited extent. Stocks like Neurocrine Biosciences ( NBIX ) are inarguably driven in large part by relatively infrequent news on clinical trial outcomes and partnering

    3. CLS: Slow Down, Think Before You Trade

      Headlines

      Wed, 15 Jan 2014

      On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine

    4. Dropping Coverage of Neurocrine

      Commentary

      Mon, 31 Aug 2009

      We are no longer providing equity research on Neurocrine Biosciences NBIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    5. Neurocrine Searches for Catalyst

      Commentary

      Tue, 16 Jun 2009

      Neurocrine Biosciences NBIX still lacks a compelling late-stage drug candidate. Its indiplon program is dead for now; the company is still waiting on final

    « Prev12Next »
    Content Partners